Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

Background Multiparametric magnetic resonance imaging (MRI), with or without MRI‐
targeted biopsy, is an alternative test to systematic transrectal ultrasonography‐guided …

Background High rates of overdiagnosis are a critical barrier to organized prostate cancer
screening. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

High-quality evidence shows that MRI in biopsy-naive men can reduce the number of men
who need prostate biopsy and can reduce the number of diagnoses of clinically insignificant …

Following detection of high levels of serum prostate-specific antigen, many men are advised
to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This …

Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …

Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

Abstract Context The Prostate Imaging Reporting and Data System (PI-RADS) 3 score
represents a “grey zone” that need to be further investigated to solve the issue of whether to …

Abstract The 2019 European Association of Urology guidelines recommend multiparametric
magnetic resonance imaging (mpMRI) for biopsy-naïve patients with clinical suspicion of …